Search Results for: The Gene Editing Institute of
Articles
SPECIAL ROUNDTABLE - Which Trends Will Have the Most Impact on Drug Development in 2022? June 6, 2022
Drug Development & Delivery posed this question to life science leaders during a recent roundtable discussion. While their responses are varied, a common theme is that COVID-19 has left a lasting impact on the industry….
Editas Medicine Announces Favorable Decision From US PTO in CRISPR Patent Interference February 28, 2022
Editas Medicine, Inc. recently announced the USPTO issued another favorable decision to the Broad Institute, Inc. (Broad) involving specific patents...Exavir Therapeutics Announces Preclinical Data Demonstrating Complete Elimination of HIV From Human Cells With LNP-Delivered Tat-Targeted CRISPR-Cas9 November 10, 2021
Exavir Therapeutics recently announced the publication of preclinical data for XVIR-TAT, Exavir’s proprietary gene editing program in early preclinical development...Servier & X-Chem Announce Drug Discovery Collaboration January 7, 2021
Servier and X-Chem, Inc. recently announced a partnership to identify and develop novel small molecules for the treatment of….
Orchard Therapeutics Announces New OTL-201 Clinical Data in Sanfilippo Syndrome Type A (MPS-IIIA) Accepted for Oral Presentation November 5, 2020
Orchard Therapeutics recently announced the presentation of new clinical data at the upcoming 62nd American Society of Hematology (ASH) Annual...Cytovia Therapeutics Partners Enters Research & Licensing Agreement With Inserm October 14, 2020
Cytovia Therapeutics recently announced it has entered a research and licensing agreement with Inserm to develop NK engager bi-specific antibodies and iPSC CAR NK cell therapy targeting….
Horizon Discovery & Pharmahungary Report Positive Early Stage Results for Novel Micro-RNA Therapeutic April 1, 2020
Horizon Discovery Group plc and Pharmahungary Group recently announced positive early stage results for a novel micro-RNA therapeutic for…………..
DRUG DISCOVERY - Zebrafish in Preclinical Drug Development - A Small Fish With Big Returns April 1, 2019
Rafael Miñana, PhD, explores the benefits of preclinical outsourcing, the value of zebrafish as an alternative model, as well as the challenges and opportunities of managing a highly diversified portfolio and providing customized solutions.
REAL ESTATE - Four Ways Firms Are Advancing Innovation With Real Estate April 1, 2019
Roger Humphrey, MBA, says as companies pursue various and unique collaborative platforms, their real estate needs are changing — with profound implications for how and where life sciences companies choose to operate.
U.S. FDA Grants Breakthrough Therapy Designation to Amicus Therapeutics February 27, 2019
Amicus Therapeutics recently announced that the US FDA has granted to Amicus a Breakthrough Therapy Designation (BTD) to AT-GAA for the treatment of late onset Pompe disease, an inherited lysosomal storage disorder caused by the deficiency of an enzyme known as acid alpha-glucosidase (GAA).
LAM Therapeutics Announces Progress of its Clinical Portfolio With FDA Clearance December 6, 2017
LAM Therapeutics, a 4Catalyzer company, advanced its clinical portfolio with the US FDA clearance of LAM’s Investigational New Drug (IND) application...CANCER IMMUNOTHERAPY - Building on Initial Successes to Improve Clinical Outcomes November 20, 2017
Allan B. Haberman, PhD, provides an updated discussion of approved and clinical-stage agents in immuno-oncology, including recently approved agents. He also addresses how researchers and companies are attempting to build on prior achievements in immuno-oncology to improve outcomes for more patients.
Oncology Venture & Eisai Forge Exclusive Global License Agreement July 12, 2017
Oncology Venture AB and 2X Oncology, Inc. recently announced that Oncology Venture has entered into an exclusive global license agreement...PLATFORM TECHNOLOGY - The 3DNA® Platform for Targeted Drug Delivery November 7, 2016
Robert C. Getts, PhD, and Jessica Bowers review how the 3DNA platform is composed entirely of noncoding DNA assembled through the sequential hybridization of single strands of DNA into a network of double-stranded nucleic acid having a controlled architecture, and multiple attachment sites for drug and targeting molecules.
Sangamo BioSciences to Acquire Biotechnology Company September 4, 2013
Sangamo BioSciences, Inc. recently announced it signed a definitive agreement to acquire Ceregene, Inc., a privately held biotechnology company focused...NIH Scientists Find That Proteins Involved in Immunity Potentially Cause Cancer July 31, 2013
A set of proteins involved in the body’s natural defenses produces a large number of mutations in human DNA, according...10/4/2011 September 27, 2011
Talon Therapeutics' NDA Accepted for Filing by US FDA Under Subpart H Talon Therapeutics, Inc. recently announced its NDA seeking...5/24/2011 May 19, 2011
Sartorius Stedim Biotech & RAUMEDIC Sign Partnership Agreement Sartorius Stedim Biotech (SSB), an international leading pharma and biotech supplier, and...
